Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A phase 2 trial of Rinatabart sesutecan in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, now recruiting.
Overview
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07288177 by Genmab, with 240 participants planned, started 2026-01-30 and due to reach its primary completion in 2027-11-22. Interventions recorded: Rina-S. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Shares Rinatabart sesutecan, Genmab.
- TrialStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re
Shares Rinatabart sesutecan, Genmab.
- TrialRAINFOL-01 (Rina-S)
Shares Rinatabart sesutecan, Genmab.
- TrialSafety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or
Shares Rinatabart sesutecan, Genmab.
- TrialPhase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Shares Rinatabart sesutecan, Genmab.
- TrialAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can
Shares Rinatabart sesutecan, Genmab.